• Home
  • Our aims
  • Services
  • References
  • R&D projects
    • SCHIZO Biomarker project
    • Epigenetic kit development
    • Developing tearproteomic depleting kit
    • Micro RNA measuring with UPL based technique
    • The Commercialisation of Transglutaminase
  • About us
  • Contact us
  • News
  • Hun
  • Eng
Services
- Functional genomic analysis services
- Epigenetic and epigenomic analysis service
References
- Partners
- Publications
- Conferences
R&D Projects
- SCHIZO Biomarker project
- Epigenetic kit development
- Tearproteomic depletion kit development
Print
16/06/11

Dividend for UDG proprietors

First time in the history of UDG

Although UDG Lts. opetares profitably since its foundation (see figures below) it is the first time that Annual Shareholders Meeting decided on paying dividend. The organisation will pay 50 percent of the after tax profit, 4.4 million HUF for proprietors.

 

Net sales from the foundation till present (million HUF)*

rtkests_N_-2010_EN

 

Net profit from the foundation till present (million HUF)*

nyeresg

*these datas come from the website of Hungarian Adminstration and the Ministri of Justice

 
Honlapkészítés Debrecen

Contact us

UD-GenoMed Medical Genomic Technologies Ltd.

University of Debrecen, Medical and Health Science Center
Debrecen Clinical Genomic Center

4032 Debrecen, Hungary, Nagyerdei krt. 98.
Theoretical Building Room 111.

Postal address: 4012 Debrecen, Hungary, Pf. 52.
Phone: +36-52-411-717 (ext. 66548)
Email: info@ud-genomed.hu

Chief Executive Officer: Gábor Zahuczky, M.Sc., Ph.D.

Phone: +36-52-411-717 (ext. 50219)
Mobile: +36-30-494-6496
Email: zahu@ud-genomed.hu